Red Blood Cells News and Research

RSS

EC grants orphan drug designation for MP4CO for treating sickle cell disease

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that the European Commission (EC) has granted orphan medicinal product designation for MP4CO for the treatment of sickle cell disease.

10 Dec 2009

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.

9 Dec 2009

Severe pandemic scenario can impact blood supplies

A German research team has examined data on supply and demand for blood transfusions against a computer simulation of an influenza pandemic, and discovered that a severe pandemic scenario could quickly lead to a deficit of up to 96,000 red blood cell (RBC) transfusion units in Germany alone, creating potentially fatal outcomes. Their study is published today in the journal TRANSFUSION.

9 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

Sickle cell disease, a condition characterized by deformed and dysfunctional red blood cells, is one of the most common genetic blood disorders affecting millions of people around the world, including more than 70,000 Americans (National Heart, Lung, and Blood Institute.

8 Dec 2009

New genetic approach may hold promise for sickle cell disease

A new genetic approach to treating sickle cell disease is showing promising results in mice, report researchers from Children's Hospital Boston. By inactivating a gene they previously discovered to be important in the laboratory, they were able to boost production of a healthy fetal form of hemoglobin in the mice, potentially compensating for the defective adult hemoglobin that causes red blood cells to "sickle" and obstruct blood flow.

8 Dec 2009

Defibrotide drug effective against hepatic veno-occlusive disease

Defibrotide, a novel drug which modulates the response of blood vessels to injury, was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease, a life threatening toxicity of transplant caused by blockages in tiny blood vessels of the liver, according to a study led by Dana-Farber Cancer Institute scientists.

8 Dec 2009

H1N1 virus causes more life-threatening complications than seasonal flu

Infection with the H1N1 virus, or swine flu, causes more life-threatening complications than seasonal flu in children with sickle cell disease, according to research from Johns Hopkins Children's Center.

8 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Alexion Pharmaceuticals, Inc. today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.

7 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

PRP shows strong potential for accelerated healing of dental implant procedures

An exciting treatment gaining acceptance in orthopedics and sports medicine, called platelet-rich plasma therapy (PRP), is showing strong potential for accelerated healing of dental implant procedures, according to a prominent dental researcher and editor of the Journal of Oral Implantology.

4 Dec 2009

NHLBI awards new federal grant to improve the quality of stored transfusion blood

A new, $2.8 million, four-year federal grant will support researchers at the University of Pittsburgh School of Medicine and their collaborators at Wake Forest University as they study why the quality of stored transfusion blood degrades over time and how to address the problem.

3 Dec 2009

Waterpipe tobacco smoking as deadly as cigarette smoking

Smoking tobacco through a waterpipe exposes the user to the same toxicants - carbon monoxide and nicotine - as puffing on a cigarette, which could lead to nicotine addiction and heart disease, according to a study led by a Virginia Commonwealth University researcher published in the December issue of the American Journal of Preventive Medicine.

3 Dec 2009

ASH to host annual High School Student Symposium at New Orleans Marriott

The American Society of Hematology (ASH) will host its annual High School Student Symposium at the New Orleans Marriott on Thursday, December 3, at 8:00 a.m. CST.

1 Dec 2009

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced that results from preclinical and clinical studies of two, novel blood forming agents, ACE-011 and ACE-536, will be presented at the 51st Annual Meeting of the American Society of Hematology at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

1 Dec 2009

New approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres discovered

Researchers at Purdue University have discovered a new approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres that could be injected into the blood shortly after an accident.

27 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

Experiments explain factors behind common malarial symptoms

When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells. Inside the blood cells, the parasites replicate and also begin to expose adhesive proteins on the cell surface that change the physical nature of the cells in the bloodstream.

23 Nov 2009

Scientists closer to unraveling the mechanisms of gene regulation

A team led by Penn State's Ross Hardison, T. Ming Chu Professor of Biochemistry and Molecular Biology, has taken a large step toward unraveling how regulatory proteins control the production of gene products during development and growth.

20 Nov 2009

Red Blood Cells News and Research

EC grants orphan drug designation for MP4CO for treating sickle cell disease

Preliminary study shows 'mini' stem cell transplantation may safely reverse severe sickle cell disease

Severe pandemic scenario can impact blood supplies

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

ASH meeting highlights H1N1 pandemic threat, new trends and treatment options for children with genetic blood disorder

New genetic approach may hold promise for sickle cell disease

Defibrotide drug effective against hepatic veno-occlusive disease

H1N1 virus causes more life-threatening complications than seasonal flu

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

New treatment options for leukemia and myeloproliferative disorders introduced

PRP shows strong potential for accelerated healing of dental implant procedures

NHLBI awards new federal grant to improve the quality of stored transfusion blood

Waterpipe tobacco smoking as deadly as cigarette smoking

ASH to host annual High School Student Symposium at New Orleans Marriott

Acceleron Pharma announces study results of its ACE-011 and ACE-536 blood forming agents

New approach for repairing damaged nerve fibers in spinal cord injuries using nano-spheres discovered

New initiative launched to take care of patients with sickle cell disease

Experiments explain factors behind common malarial symptoms

Scientists closer to unraveling the mechanisms of gene regulation

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News